Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Post-traumatic Stress Disorder (PTSD) Treatment Market

Post-traumatic Stress Disorder (PTSD) Treatment Market Share

Report ID: GMI10554
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Post-traumatic Stress Disorder Treatment Market Share

The PTSD treatment industry is highly fragmented, with large multinationals and smaller companies competing. Major pharmaceutical firms are developing and marketing both established and novel medications, such as antidepressants and anxiolytics, to manage PTSD symptoms. The market is dynamic and competitive, driven by continuous innovation and a focus on improving patient outcomes.

Post-traumatic Stress Disorder Treatment Market Companies

Prominent players operating in the post-traumatic stress disorder treatment industry include:

AstraZeneca Plc
Aurobindo Pharma Limited
Bionomics
Camber Pharmaceuticals, Inc.
Eli Lilly and Company
GSK plc
H. Lundbeck A/S
Jazz Pharmaceuticals plc
Johnson & Johnson Services, Inc.
Lupin Pharmaceuticals, Inc.
Merck & Co., Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Pfizer, Inc.
Takeda Pharmaceutical Company Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global post-traumatic stress disorder treatment industry was valued at USD 13.2 billion in 2023 and is expected to exhibit a CAGR of 4.4% from 2024 to 2032, attributed to the ongoing advancements in treatment options, increasing incidence and prevalence of PTSD, rise in mental health awareness.

The antidepressants segment generated the highest revenue of USD 6.5 billion in 2023, as they are commonly prescribed for PTSD due to their effectiveness in alleviating core symptoms such as depression, anxiety, and intrusive thoughts.

North America PTSD treatment market accounted for USD 5.4 billion in 2023 and is anticipated to record a CAGR of 4.2% over 2024-2032 as the region has a well-established healthcare infrastructure, characterized by advanced medical facilities, specialized mental health centers, and a broad network of healthcare professionals.

Camber Pharmaceuticals, Inc., Eli Lilly and Company, GSK plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Johnson & Johnson Services, Inc., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., and Novartis AG among others.